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Abstract
Background Androgen deprivation therapy has been
associated with worsened body image in prostate cancer
patients. Body image and physical presentation changes
were investigated in patients receiving a gonadotropin-re-
leasing hormone analogue (triptorelin) as part of treatment
for locally advanced or metastatic prostate cancer.
Objective The aim was to evaluate the changes in self-
perception of the body and to assess the relationship of
these changes over a period of 2 years in men treated with
triptorelin as primary therapy for advanced or locally
advanced prostate cancer.
Methods Data were collected for 2 years in accordance
with routine clinical practice. Body image was assessed
using the body image scale (BIS). Patient body mass index
(BMI) and waist circumference were also measured.
Results BIS and BMI data for both baseline and a least one
post-baseline visit were available for 98 of the 145 patients
enrolled. The median change in BIS score for patients
assessed around 12 or 24 months after baseline and at the last
observation was zero, indicating no body image deterioration
in at least half of patients. Statistically significant BIS score
increases were detected in assessments around 6, 12 and
18 months, but not after 2 years, indicating some patients
experienced body image deterioration at some point during
treatment. Changes in BMI from baseline were modest and
generally not statistically significant. Waist circumference
increased during the study (mean ± standard deviation
increase of 1.00 ± 5.01 cm at the last observation). Positive
correlations were determined between increases in BIS score
and both BMI and waist circumference (r = 0.235 and 0.267,
respectively; p = 0.020 and 0.008) at the last observation for
all patients, as well as during the second year of the study.
Conclusions Most patients did not experience clinically
meaningful worsening of body image perception during the
study. BMI and waist circumference had a modest impact
on body image during study year 2.
Key Points
The majority of prostate cancer patients treated for
over 2 years with triptorelin did not experience a
clinically meaningful worsening of body image.
Changes in BMI and waist circumference had a
modest impact on body image.
1 Introduction
Prostate cancer is the most commonly occurring new
cancer in European men, with an estimated 416,700 new
cases in 2012, corresponding to an age-standardised
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incidence of 96.0 per 100,000 [1]. Despite the reported
high incidence of prostate cancer, the mortality is relatively
low (age-standardised mortality rate of 19.3 per 100,000)
[1], with 5-year survival rates in excess of 80% reported in
most European countries in the period between 2005 and
2009 [2]. Both the incidence of and the survival rate from
prostate cancer are increasing [1, 2], leading to a growing
population of cancer survivors with long-term comorbidi-
ties (increased risk for diabetes, bone deterioration and
increase in high-density lipoprotein cholesterol) associated
with prostate cancer and its treatment [3].
Proliferation of prostate cancer cells is mediated by the
androgen receptor, which is primarily activated by dihy-
drotestosterone, an active metabolite of testosterone [4].
Consequently, androgen deprivation therapy (ADT) is one
of the major treatments for advanced or metastatic prostate
cancer, with almost half of all prostate cancer patients
receiving some form of ADT during the course of their
disease [5]. The side effects of ADT therapy are well-
characterised, and include osteoporosis and loss of libido,
as well as increased body fat and decreased muscle mass
[6–10]. The physical changes in patients treated with ADT
have been associated with worsening body image percep-
tion, and a concomitant negative impact on quality of life
[11].
A previous study investigating body image perception in
patients with prostate cancer reported that patients receiv-
ing ADT experienced significantly greater dissatisfaction
with their body image than ADT-naı¨ve patients [11]. In the
overall study population, increased body image dissatis-
faction correlated to higher body mass index (BMI) [12].
Harrington et al. [12] measured body image perception
using the body image scale (BIS), a validated, reliable
questionnaire for use with cancer patients [13]. The BIS
contains ten Likert-like items relating to self-consciousness
about appearance, physical attractiveness, dissatisfaction
with appearance, feeling less feminine/masculine, finding it
difficult to look at oneself naked, feeling less sexually
attractive, avoiding people due to one’s appearance, feeling
treatment has left the body less whole, dissatisfaction with
one’s own body, and dissatisfaction with the appearance of
a scar [13].
Available ADT treatments for locally advanced or
metastatic prostate cancer include triptorelin (Decapeptyl,
Ipsen), a gonadotropin-releasing hormone (GnRH) ana-
logue. Chronic and continuous triptorelin administration
leads to decreased luteinising hormone and suppression of
testicular steroidogenesis [14, 15]. The purpose of the
current observational study was to investigate changes in
body image perception in patients with locally advanced or
advanced prostate cancer receiving triptorelin as body
image seems to play an important role in these patients
[11]. Body image was assessed using a modified nine-item
version of the BIS (excluding the question relating to the
appearance of a scar, which was not relevant in this con-
text). In addition, changes in BMI and waist circumference
were measured to assess whether changes in body image
perception were related to changes in physical presentation
experienced by patients receiving triptorelin.
2 Methods
The present study was a prospective, observational, mul-
ticentre study conducted between 25 January 2010 and
30 April 2014 at 18 sites in Belgium, the majority being
hospitals. Sites were selected after a qualification visit for
both the study target population and logistics to conduct
clinical studies. The study received ethics committee
approval as required by Belgian law for non-interventional
studies.
2.1 Patients
The study enrolled adult men aged 50 years or older with
locally advanced or metastatic prostate cancer who were
scheduled to receive triptorelin. As this was a non-inter-
ventional study, the decision to prescribe triptorelin was
made prior to, and independently from, the decision to
enrol a patient in the study. Patients receiving, or scheduled
to receive, docetaxel chemotherapy, radical prostatectomy
or radiotherapy were excluded from the study; as were
patients who had received any investigational drug in the
3 months before study entry. Patients who had radical
prostatectomy or radiotherapy prior to inclusion in the
study were allowed to participate. Patients were followed
in the study until their routine hospital visit closest to study
week 104.
2.2 Study Visits
As this was an observational study, the timing of study
visits was not determined in the study protocol, but
reflected the normal interaction between patient and
physician. Patients were assessed during their usual hos-
pital visits. To allow changes in measurements to be
assessed over time, study visits were allocated to ‘time
windows’ of approximately 90 days, as follows: day 1
(baseline); month (M) 3 (target day 92); M 6 (target day
184); M 9 (target day 275); M 12 (target day 366); M 15
(target day 458); M 18 (target day 549); M 21 (target day
640) and M 24 (target day 732). If more than one visit fell
into the same window, the closest to the target day was
retained. As the timing of visits was according to routine
practice at the individual study site, not all patients were
assessed during each time window. In addition, data for the
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non-baseline study visit nearest week 104 (last observa-
tion) were summarised for all patients.
2.3 Assessments
Patient body image perception was assessed with a modi-
fied version of the BIS [13]. The full BIS questionnaire was
used, with the exception of the question, ‘‘Have you been
dissatisfied with the appearance of your scar?’’ Responses
to individual questions were on a 0–3 scale (0 = not at all,
3 = very much), and a total BIS score was calculated for
all nine items used, to give a score out of 27 (where higher
scores indicate worse body image perception).
Patient height, weight and waist circumference were
measured at baseline. Weight and waist circumference
were measured at subsequent study visits. Study data were
presented using summary statistics. Measurements at each
time window and at the last observation were compared
with baseline values by paired t test. Correlations between
changes in BMI and waist circumference and changes in
total BIS score were determined by Pearson correlation
coefficient. Student’s t test was used to compare Pearson
correlation coefficients with 0.
3 Results
A total of 145 patients provided signed informed consent
and were enrolled in the study, 138 of whom received
triptorelin. Of the 138 patients treated, 106 completed the
study. Patient flow through the study is summarised in
Fig. 1. Total BIS score and BMI data were available for a
total of 98 triptorelin-treated patients. Demographic and
baseline disease data for these patients are presented in
Table 1. The patients assessed in this study were predom-
inantly elderly [mean ± standard deviation (SD) age
77.8 ± 7.1 years] and the majority (98%) were Caucasian.
The most common indication for treatment was first-line
therapy for locally advanced prostate cancer (46.9% of
patients), and the most frequently prescribed triptorelin
dose was 11.25 mg.
Changes in total BIS score, BMI and waist circum-
ference from baseline are presented in Fig. 2. Higher BIS
scores indicate worsening body image. There was con-
siderable variation in the number of patients assessed at
each time window, with most patients being assessed at
M 12 and M 24. As this is a non-interventional study, this
reflects clinical practice at the study sites. Changes in
total BIS score, BMI and waist circumference at M 12,
M 24 and the last observation are summarised in Table 2.
At baseline, both mean and median BMI were consistent
with recorded mean values for adult Belgian males
(26.78 kg/m2 in 2008 [16]). Mean and median waist cir-
cumference was below 102 cm at baseline, which is
considered the point beyond which there are considerable
Fig. 1 Study flowchart: patient disposition. Data were evaluated for
the 98 patients who received triptorelin and had body image scale
(BIS) and body mass index (BMI) data available for baseline and at
least one other study visit
Table 1 Study population characteristics (age, race, Gleason score,




Age, years Mean ± SD 77.8 ± 7.1
Median 79.0
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11.25 mg 85 (86.7)
22.50 mg 5 (5.1)
PSA prostate specific antigen, SD standard deviation, TURP transur-
ethral resection of the prostate
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health risks associated with being overweight for a male
patient [17].
Notably, the median change in total BIS score recorded
at both M 12 and M 24 was 0.0. At the last observation, the
median change recorded for the whole population was also
0.0, indicating that at least half of the patients in the study
did not perceive any worsening in body image (Table 2).
Despite this, statistically significant increases in
mean ± SD BIS score were recorded at M 6 (0.9 ± 2.5,
p = 0.018), M 12 (1.4 ± 3.8, p = 0.008) and M 18
(3.0 ± 4.2, p = 0.001; Fig. 2a) as well as at the last
observation for all patients (1.1 ± 4.5, p = 0.017;
Table 2). These data indicate that some patients reported
significant worsening of body image at these time windows
and at the end of the study. Interestingly, smaller mean
increases from baseline BIS score were recorded at M 24
(1.1 ± 4.9) compared with the preceding time windows,
and this change was not statistically significant
(p = 0.068), suggesting that patients may experience some
acceptance of body image changes over 2 years (Fig. 2a).
When responses to individual BIS questions were com-
pared between baseline and the last observation for all
patients (see Fig. 3), mean scores increased notably during
triptorelin treatment for seven of the nine items. Exceptions
included question 1 (‘‘Have you been feeling self-conscious
about your appearance?’’), where mean scores were lower at
the end of study compared to baseline, and question 7 (‘‘Did
you avoid people because of the way you felt about your
appearance?’’), where mean scores were similar at baseline
and the last observation. The lack of change inmean score for
question 7 is not surprising given the nature of the body image
changes experienced by patients in this study (Fig. 2b, c).
Responses to question 1 at baseline and the last observation
suggest a degree of self-consciousness due to appearance at
baseline, which reduced at the last observation.
Mean values for BMI were comparable to baseline for
most time windows (Fig. 2b). A statistically significant
increase in BMI from baseline was recorded during M 18
only (mean ± SD 0.47 ± 1.20 kg/m2, p = 0.048). There
was a trend towards increasing waist circumference
throughout the study (Fig. 2c), with statistically significant
mean ± SD increases in waist circumference recorded at
M 12 (0.78 ± 2.94 cm, p = 0.041), M 18 (2.45 ± 3.48 cm,
p\ 0.001) and M 24 (1.45 ± 5.32 cm, p = 0.024). Weak
but statistically significant correlations were calculated
between changes in BIS and changes in both BMI and waist
circumference at M 24 (r = 0.300 and 0.331, respectively;
p = 0.015 and 0.007) and the last observation (r = 0.235
and 0.267; p = 0.020 and 0.008), but not at M 12 (Table 2),
suggesting that changes in BMI and waist circumference
contributed to patients body image perception during the
second year of treatment.
4 Discussion
The median change in total BIS score from baseline for
patients assessed at approximately 12 and 24 months and at
the last observation for all subjects was zero. This indicates
Fig. 2 Mean change in a total body image scale (BIS) score, b body
mass index (BMI) and c waist circumference at each time window.
Error bars represent 95 % confidence intervals. Asterisk indicates a
statistically significant change from baseline (p\ 0.05). M month
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that at least half of patients assessed did not report wors-
ening body image perception at these time points. Statis-
tically significant mean increases in BIS score were
recorded during some time windows and the last
observation, suggesting that, while body image remained
unchanged or improved for most patients, some patients
did experience worsening of body image perception at
some point during triptorelin treatment.
Table 2 Change from baseline in physical presentation characteristics
Characteristic Statistic Baseline Change from baseline
M 12 M 24 Last observation
BIS N 98 56 67 98
Mean ± SD 3.0 ± 3.8 1.4 ± 3.8 1.1 ± 4.9 1.1 ± 4.5
Median 2.0 0.0 0.0 0.0
Range 0–19 -14 to 9 -16 to 13 -16 to 13
P value – 0.008 0.068 0.017
BMI (kg/m2) N 98 62 72 98
Mean ± SD 26.82 ± 2.04 0.13 ± 1.27 0.26 ± 1.75 0.09 ± 1.70
Median 26.20 0.04 0.39 0.00
Range 18.2–38.8 -5.0 to 4.3 -6.7 to 4.1 -6.7 to 4.1
P value – 0.412 0.209 0.621
Pearson correlationa (p value) – 0.117 (0.392) 0.300 (0.015) 0.235 (0.020)
Waist circumference (cm) N 97 62 71 97
Mean ± SD 98.59 ± 14.23 0.78 ± 2.94 1.45 ± 5.32 1.00 ± 5.01
Median 98.00 0.00 1.00 0.70
Range 64.0–139.0 -8.0 to 8.0 -11.0 to 16.5 -11.0 to 16.5
P value – 0.041 0.024 0.052
Pearson correlationa (p value) – 0.234 (0.083) 0.331 (0.007) 0.267 (0.008)
BIS body image scale, BMI body mass index, M month, SD standard deviation
a With change in total BIS score
A
B
Fig. 3 a Change in mean score
between baseline and last
observation for each item of the
modified body image scale
(BIS) questionnaire.
b Questions in the BIS used.
Adapted from Hopwood et al.
[13]. An increase in BIS score
indicates worsening of body
image
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Body image has been associated with quality of life in
patients with prostate cancer [11, 18]. Patients receiving
treatment for prostate cancer typically experience a series
of physical changes that may impact body image, including
reduced penile length, reduced lean muscle mass and
increased body fat [8, 19]. In a study of body image per-
ception in prostate cancer patients, those receiving ADT
experienced worse body image perception, and negative
body image correlated with higher BMI [12]. It is unclear
from the study by Harrington et al. [12] the extent to which
the differences between ADT-treated and ADT-naı¨ve
patients were due to the different treatments received, as
patient disease parameters were not presented.
Where statistically significant mean changes in BIS
score were reported, these were generally low in the con-
text of a 27-point scale, with mean increases between 0.9
(M 6) and 3.0 (M 18). There are no publications indicating
what constitutes a clinically meaningful increase in BIS
score. However, the mean scores measured throughout the
study were generally low and consistent with patients
answering ‘‘not at all’’ to most of the items in the BIS
questionnaire, indicating that patients had a generally
positive perception of body image during this study. In
addition, while significant changes in total BIS score were
reported for patients assessed at M 6, M 12 and M 18,
increases in BIS score appeared to diminish by M 24,
where changes from baseline were no longer statistically
significant. This finding could be interpreted as patients
developing some acceptance of the physical changes they
are undergoing. However, as not all patients were assessed
during each time window, comparisons of BIS score
between windows should be interpreted with caution.
Currently, the BIS is the only validated tool for
assessing body image in cancer patients. For this study, the
modified BIS (discounting the question regarding the
appearance of a scar) was the most appropriate instrument
to use in this study since only 12.2 % of the patients
underwent a radical prostatectomy. In the future, more
suitable patient-reported outcomes could be developed to
address the potential impact of physical changes experi-
enced by patients receiving treatment for prostate cancer.
When changes in individual items of the BIS were con-
sidered in the current study, mean scores indicated wors-
ening body image in all but two aspects investigated in the
questionnaire (avoiding interaction with people and feeling
self-conscious about one’s appearance). Given the nature
and extent of the physical presentation changes experienced
by patients during this study, the finding that there was little
change in the number of patients who avoided people
because of the way they felt about their appearance at their
last observation compared with baseline is perhaps unsur-
prising. Interestingly, patients appeared to report feeling
less self-conscious about their appearance at their last
observation compared with baseline. The responses to this
question indicated that this was the biggest contributor to
negative body image at baseline and last observation
(Fig. 3a). The reasons for this change are unclear, but this
suggests that the factors affecting body image in prostate
cancer patients are complex, and may change over time.
In the current study, a weak correlation was detected
between increase in BIS score and increase in BMI at the
last observation, and in the M 24 time window, suggesting
that changes in body image are partly linked to changes in
BMI after prolonged treatment in patients receiving trip-
torelin for prostate cancer.
Interestingly, the mean change in BMI between baseline
and the last observation in this study was not statistically
significant, and there was no change in the median BMI
(Table 2). Statistically significant increases in BMI from
baseline were measured for patients assessed at M 18 only
(Fig. 2b), suggesting that most patients receiving triptorelin
did not experience notable weight gain during this study.
The risk of weight gain with ADT is significantly higher
in patients who are obese (BMI C30.0 kg/m2) compared
with in those whose BMI indicates they are ‘normal’
(18.5–24.9 kg/m2) or ‘overweight’ (25.0–29.9 kg/m2) [20].
Although patients with BMI values as high as 38.8 kg/m2
were enrolled, the mean baseline BMI recorded in this
study was consistent with that for the Belgian male popu-
lation [17], and the majority of patients were overweight,
rather than obese, and therefore less at risk of experiencing
considerable weight gain.
Waist circumference did appear to increase during the
study, with statistically significant increases measured
during M 12, M 18 and M 24 (Fig. 2c). Both mean and
median waist circumference increased from baseline to last
observation, although these increases were not statistically
significant (Table 2). This finding, combined with the
modest and non-significant increases in BMI experienced
by patients in the study are consistent with other studies of
patients receiving GnRH analogues, where patients expe-
rience decreased lean mass in combination with increased
fatty deposits [7, 10]. These findings suggest that some
patients may be at increased risk of developing ‘sarcopenic
obesity’ [21], and that the potential for this to occur should
be considered even in the absence of an increase in BMI.
Increase in total BIS score was found to correlate
weakly with increase in waist circumference at the last
observation, and more strongly for the M 18 and M 24
time windows (r = 0.492 and 0.331, respectively). These
findings suggest that changes in waist circumference pre-
dict changes in body image in patients receiving triptorelin
for prostate cancer, and that waist circumference may be a
better indicator of body image perception than BMI in this
patient population, particularly in patients receiving trip-
torelin for more than 1 year.
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5 Conclusion
The results of this study add to the currently limited evi-
dence base addressing issues of body image in patients
with prostate cancer. The data suggest that most patients
did not experience significant deterioration in body image
perception, indicating that significant worsening of body
image perception is most likely experienced by a minority
of patients. Changes in body image were found to corre-
late weakly with both BMI and waist circumference.
Further study, potentially in a larger population of
patients, is necessary to establish which patient groups
experience the largest effects in body image (and therefore
potentially the greatest emotional and psychological
impact on wellbeing and quality of life) during treatment
with GnRH analogues.
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